The Hague, The Netherlands, 4 December 2025 – Koralis, advising technology and science innovators on corporate narrative and investor relations strategy, today announced the appointment of Dr. Artal Moreno-Fortuny as Senior Advisor.

For ambitious companies, the market narrative is a live instrument of strategy. It is continuously tested by investors, reshaped by activists, and benchmarked in partnership due diligence. In this environment, communication must be architecturally sound—built to not only protect value but to systematically advance it.

Dr. Moreno-Fortuny's experience is central to this strategic build-out. He brings a lens forged in the transaction groups of Novo Nordisk and Novartis, where he specialized in valuing external innovation. His work translates the complexity of scientific breakthroughs into the clear risk-reward frameworks that govern institutional capital allocation and strategic partnerships.

"Our mandate is to ensure a company's strategic narrative is fully capitalized—in trust, in partnership, and in valuation," said Aisha Lindman, Founding Partner of Koralis. "Artal has operated at the nexus where that capitalization happens. Integrating his perspective allows us to equip leadership with the rigor that turns market engagement into a tangible advantage. This depth of preparation is the foundation of our advisory model."

"Koralis operates at the critical intersection of science, narrative, and capital," commented Dr. Artal Moreno-Fortuny. "My focus is on strengthening the connective tissue between a company's potential and its recognized value. I look forward to contributing to a platform built for strategic impact."

Dr. Moreno-Fortuny will provide strategic counsel to Koralis, with a focus on the life sciences sector.